Compare Global X CleanTech (CTEC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs Zimmer Biomet Holdings Inc — how do they compare? Global X CleanTech trades at $56.49, while Zimmer Biomet Holdings Inc trades at $89.45 (market cap $17.61B). The key difference: Zimmer Biomet Holdings Inc pays a 1.05% dividend while Global X CleanTech pays none. Which is the better fit depends on your goals.
| CTEC | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $107.71 |
52-Week Low | $39.45 | $79.58 |
Market Cap | — | $17.61B |
Enterprise Value | — | $24.66B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $57.34, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure but oscillators showing potential oversold conditions. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. The company has announced a future dividend of $0.07 per share payable in July 2026, though recent earnings and cash flow data are not provided.
The outlook remains cautious due to weak technical momentum and incomplete financial disclosure. Investment opportunity hinges on upcoming financial results revealing profitability and growth, while risks include persistent selling pressure and lack of current fundamental visibility. Investors await clearer earnings updates to assess valuation and business health.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
